[1] 原伟, 严伟明, 宁琴. 慢性乙型肝炎临床免疫学研究进展. 中国医师杂志, 2017, 19: 7-13.
[2] 朱其荣, 王川林, 刘娇,等. 分子吸附再循环系统对肝衰竭患者血清Th1/Th2型细胞因子水平的影响. 实用肝脏病杂志, 2017, 20: 107-108.
[3] 姚云洁, 杨才兴, 巫继. 恩替卡韦联合复方鳖甲软肝片治疗慢性乙型肝炎患者疗效观察. 实用肝脏病杂志, 2015, 18: 356-359.
[4] 李凌燕. 彩色多普勒超声评价安络化纤丸治疗慢性乙型肝炎的疗效研究. 中西医结合肝病杂志, 2015, 25: 236-238.
[5] 中华医学会肝病学分会,中华医学会感染病学分会. 慢性乙型肝炎防治指南(2015更新版). 中华传染病杂志, 2015, 33: 641-662.
[6] Shirin D, Geoffrey D. The current treatment situation and definitions of a cure for chronic HBV infection. Future Virol, 2016, 11: 79-92.
[7] 张毅, 余永胜, 王洁玲,等. Runx3过表达对慢性乙型肝炎患者Th1、Th2型细胞因子表达的影响. 肝脏, 2015, 20: 359-363.
[8] 石栓柱, 陈翛然, 古玉茹,等. 安络化纤丸联合恩替卡韦对乙型肝炎肝硬化患者门静脉系统血流动力学研究. 中西医结合肝病杂志, 2016, 26: 336-337, 373.
[9] Boglione L, Cariti G, Di Perri G, et al. Sequential therapy with entecavir and pegylated interferon in a cohort of young patients affected by chronic hepatitis B. J Med Vir, 2016, 88: 1953-1959.
[10] Yuen MF, Ahn SH, Lee KS, et al. Two-year treatment outcome of chronic hepatitis B infection treated with besifovir vs. entecavir: results from a multicentre study. J Hepatol, 2015, 62: 526-532. |
